Pfizer Takes a Flogging
The news didn't bother Michael Krensavage of Raymond James, who told clients that he was keeping a strong buy rating. Even though third-quarter revenue fell by 5%, that was a smaller decline than Krensavage had predicted.
And while Pfizer's third-quarter profit was 51 cents, excluding items, that was 4 cents better than Krensavage had forecast. He doesn't own shares, but his firm says it expects to receive or intends to seek investment-banking compensation from companies mentioned in its research reports.
Meanwhile, James Kelly of Goldman Sachs says his estimates are under review. His research note says he still has an outperform rating on Pfizer. He doesn't own shares, and his firm has had an investment banking relationship with the company.
The Cholesterol Connection
Part of the problem is Lipitor, the anti-cholesterol drug whose U.S. revenue rose just 1% in the quarter due to "an unexpectedly rapid slowdown in the U.S. lipid-lowering market as a whole and marginal Lipitor prescription share erosion during the quarter of one percentage point," the company said.The company said the rate of growth in new prescriptions in the overall lipid-reducing market was 8% in the third quarter, down from 17% in the first half of the year. Pfizer said its drug still commands 40% of all lipid-lowering prescriptions, well above any competitor. "We believe that Lipitor is poised for further growth fueled by newly emergent outcomes data, which once again confirm Lipitor's outstanding ability to reduce morbidity associated with cardiovascular disease," Pfizer said. "We believe that these new data will support renewed growth for Lipitor. These data will also be prominently featured in upcoming physician and consumer branded and unbranded promotion beginning this quarter." Lipitor's foreign-market sales came to the rescue, adding 14% for the quarter. Worldwide Lipitor sales rose 6% to $2.9 billion.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV